$FBRX
Forte Biosciences, Inc.

2019 Q2 Form 10-Q Financial Statement

#000156459019030897 Filed on August 08, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q2 2018 Q1
Revenue $9.000K $9.000K $0.00
YoY Change 0.0% -10.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.850M $2.570M $2.420M
YoY Change 88.72% 26.6% 24.74%
% of Gross Profit
Research & Development $11.97M $12.76M $10.44M
YoY Change -6.21% 92.45% 57.55%
% of Gross Profit
Depreciation & Amortization $210.0K $120.0K $95.00K
YoY Change 75.0% 100.0% 46.15%
% of Gross Profit
Operating Expenses $16.82M $15.34M $12.86M
YoY Change 9.7% 77.05% 50.11%
Operating Profit -$15.33M -$12.85M
YoY Change 77.15% 50.19%
Interest Expense -$300.0K -$760.0K -$30.00K
YoY Change -60.53% 85.37% -94.23%
% of Operating Profit
Other Income/Expense, Net -$299.0K -$762.0K -$34.00K
YoY Change -60.76% -93.46%
Pretax Income -$17.11M -$16.09M -$12.88M
YoY Change 6.34% 77.4% 42.01%
Income Tax
% Of Pretax Income
Net Earnings -$630.0K -$16.09M -$12.88M
YoY Change -96.08% 77.47% 41.96%
Net Earnings / Revenue -7000.0% -178766.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$10.83M -$12.10M -$9.684M
COMMON SHARES
Basic Shares Outstanding 19.91M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2018 Q2 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $68.32M $79.46M $74.00M
YoY Change -14.02% -26.83% 156.18%
Cash & Equivalents $18.90M $24.61M $17.79M
Short-Term Investments $49.43M $54.85M $56.21M
Other Short-Term Assets $4.500M $4.000M $3.100M
YoY Change 12.5% 300.0% 158.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $72.79M $83.50M $77.10M
YoY Change -12.83% -23.81% 156.67%
LONG-TERM ASSETS
Property, Plant & Equipment $3.657M $3.700M $1.400M
YoY Change -1.16% 311.11% 90.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.025M $200.0K $200.0K
YoY Change 412.5% -33.33% -94.32%
Total Long-Term Assets $12.45M $3.800M $1.600M
YoY Change 227.5% 216.67% -62.41%
TOTAL ASSETS
Total Short-Term Assets $72.79M $83.50M $77.10M
Total Long-Term Assets $12.45M $3.800M $1.600M
Total Assets $85.23M $87.30M $78.70M
YoY Change -2.37% -21.21% 129.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.501M $1.500M $1.800M
YoY Change 66.73% 15.38% 90.07%
Accrued Expenses $10.38M $11.20M $7.900M
YoY Change -7.31% 67.16% 0.56%
Deferred Revenue $36.00K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.400M $7.200M
YoY Change 0.0%
Total Short-Term Liabilities $17.31M $13.77M $16.90M
YoY Change 25.73% -9.43% 5.13%
LONG-TERM LIABILITIES
Long-Term Debt $22.08M $25.91M $2.000M
YoY Change -14.8% 275.55% -76.7%
Other Long-Term Liabilities $9.400M $1.600M $200.0K
YoY Change 487.5% 1500.0% 100.0%
Total Long-Term Liabilities $22.08M $25.91M $2.200M
YoY Change -14.8% 270.19% -74.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.31M $13.77M $16.90M
Total Long-Term Liabilities $22.08M $25.91M $2.200M
Total Liabilities $48.75M $41.25M $19.06M
YoY Change 18.19% 85.8% -46.76%
SHAREHOLDERS EQUITY
Retained Earnings -$250.1M -$179.8M
YoY Change 31.18%
Common Stock $286.5M $239.6M
YoY Change 5669.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.548M $46.09M $59.68M
YoY Change
Total Liabilities & Shareholders Equity $85.23M $87.30M $78.74M
YoY Change -2.37% -21.21% 129.6%

Cashflow Statement

Concept 2019 Q2 2018 Q2 2018 Q1
OPERATING ACTIVITIES
Net Income -$630.0K -$16.09M -$12.88M
YoY Change -96.08% 77.47% 41.96%
Depreciation, Depletion And Amortization $210.0K $120.0K $95.00K
YoY Change 75.0% 100.0% 46.15%
Cash From Operating Activities -$18.16M -$10.76M -$12.71M
YoY Change 68.77% 46.39% 67.87%
INVESTING ACTIVITIES
Capital Expenditures -$130.0K -$660.0K $220.0K
YoY Change -80.3% 1000.0% 315.09%
Acquisitions
YoY Change
Other Investing Activities -$280.0K $1.450M -$3.440M
YoY Change -119.31% -113.68% -190.05%
Cash From Investing Activities -$410.0K $790.0K -$3.661M
YoY Change -151.9% -107.42% -197.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $29.00K
YoY Change -29.27%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.470M 16.79M -1.771M
YoY Change -61.47% -80.74% -133.8%
NET CHANGE
Cash From Operating Activities -18.16M -10.76M -12.71M
Cash From Investing Activities -410.0K 790.0K -3.661M
Cash From Financing Activities 6.470M 16.79M -1.771M
Net Change In Cash -12.10M 6.820M -18.14M
YoY Change -277.42% -90.14% -1359.72%
FREE CASH FLOW
Cash From Operating Activities -$18.16M -$10.76M -$12.71M
Capital Expenditures -$130.0K -$660.0K $220.0K
Free Cash Flow -$18.03M -$10.10M -$12.93M
YoY Change 78.51% 38.55% 69.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1025000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1360000
CY2018Q4 us-gaap Assets
Assets
103081000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2501000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3404000
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10381000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16534000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17308000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23000151
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23000151
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2344000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24613000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
274029000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215884000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
36486000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85234000
dei Entity Address Address Line1
EntityAddressAddressLine1
4242 Campus Point Court
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Local Phone Number
LocalPhoneNumber
412-8400
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18898000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40813000
CY2019Q2 us-gaap Marketable Securities
MarketableSecurities
49426000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
58145000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103081000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9000
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 500
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
261243872
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei City Area Code
CityAreaCode
858
dei Entity File Number
EntityFileNumber
001-38052
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018Q4 us-gaap Marketable Securities
MarketableSecurities
55273000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4465000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1662000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
72789000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
97748000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3657000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3973000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7763000
CY2019Q2 us-gaap Assets
Assets
85234000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13094000
CY2019Q2 us-gaap Notes Payable Current
NotesPayableCurrent
4408000
CY2019Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
18000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
36000
CY2019Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
22079000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
26201000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9361000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2201000
CY2019Q2 us-gaap Liabilities
Liabilities
48748000
CY2018Q4 us-gaap Liabilities
Liabilities
44936000
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
23000
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
286489000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-250082000
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
56000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-23000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-299000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-762000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-512000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-796000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
44854000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
298000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6062000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
38000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
298000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7566000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4344000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
79000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
59678000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2018Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
290000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1672000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
479000
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
54000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
46089000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
71082000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
34000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
290000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3193000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
479000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-20000
us-gaap Share Based Compensation
ShareBasedCompensation
4344000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9000
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18000
CY2019Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2018Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap Net Income Loss
NetIncomeLoss
-34198000
CY2018Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
54000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
79000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17076000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16035000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.81
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23673061
CY2019Q2 toca Working Capital
WorkingCapital
55500000
us-gaap Share Based Compensation
ShareBasedCompensation
3193000
us-gaap Depreciation
Depreciation
433000
us-gaap Depreciation
Depreciation
222000
us-gaap Paid In Kind Interest
PaidInKindInterest
286000
us-gaap Paid In Kind Interest
PaidInKindInterest
873000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
22000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
86000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4229000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-18000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
982000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
232000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
495000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35843000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23471000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
48947000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
28444000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5691000
toca Proceeds From Issuance Of Notes Payable Net Of Issuance Costs
ProceedsFromIssuanceOfNotesPayableNetOfIssuanceCosts
26325000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
8631000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8237000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15018000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-21915000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-11320000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35933000
us-gaap Interest Paid Net
InterestPaidNet
1231000
us-gaap Interest Paid Net
InterestPaidNet
427000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
37000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
733000
toca Deferred Equity Issuance Cost Payment Reclassified To Equity Upon Sales Under At The Market Offering Facility
DeferredEquityIssuanceCostPaymentReclassifiedToEquityUponSalesUnderAtTheMarketOfferingFacility
108000
toca Allowance For Tenant Improvements
AllowanceForTenantImprovements
1054000
toca Fair Value Of Common Stock Warrants Issued In Connection With Notes Payable
FairValueOfCommonStockWarrantsIssuedInConnectionWithNotesPayable
479000
CY2019Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
68300000
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4599344
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial statements are prepared in accordance with GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Significant estimates in the Company&#8217;s financial statements relate to clinical trial accruals, the valuation of equity awards, and the development period used for license revenue recognition. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results may differ from these estimates under different assumptions or conditions.</p>
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3616085
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4599344
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3616085
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
836000
CY2019Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2019Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
49370000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
55296000
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
56000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
26000
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
49426000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
55273000
us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
0
CY2019Q2 toca Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
3830000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1955000
CY2019Q2 toca Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
1083000
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
283000
CY2019Q2 us-gaap Interest Payable Current
InterestPayableCurrent
204000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2190000
CY2019Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5434296
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3193000
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company leases its office and laboratory space located in San Diego, California, for its corporate headquarters and research facility under an operating lease agreement (the Lease). The Lease commenced in March 2018.
toca Lessee Operating Lease Commenced Period
LesseeOperatingLeaseCommencedPeriod
2018-03
CY2019Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P8Y
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
the Company has one option to extend the Lease for a period of five additional years.
toca Lessee Operating Lease Additional Term Of Contract
LesseeOperatingLeaseAdditionalTermOfContract
P5Y
toca Lessee Operating Lease Tenant Improvement Allowance
LesseeOperatingLeaseTenantImprovementAllowance
1200000
toca Lessee Operating Lease Term Of Terminate
LesseeOperatingLeaseTermOfTerminate
P9M
CY2019Q2 toca Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
0.109

Files In Submission

Name View Source Status
0001564590-19-030897-index-headers.html Edgar Link pending
0001564590-19-030897-index.html Edgar Link pending
0001564590-19-030897.txt Edgar Link pending
0001564590-19-030897-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
toca-10q_20190630.htm Edgar Link pending
toca-20190630.xml Edgar Link completed
toca-20190630.xsd Edgar Link pending
toca-20190630_cal.xml Edgar Link unprocessable
toca-20190630_def.xml Edgar Link unprocessable
toca-20190630_lab.xml Edgar Link unprocessable
toca-20190630_pre.xml Edgar Link unprocessable
toca-ex101_352.htm Edgar Link pending
toca-ex102_353.htm Edgar Link pending
toca-ex311_6.htm Edgar Link pending
toca-ex312_15.htm Edgar Link pending
toca-ex321_12.htm Edgar Link pending